Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIVEBETTER
NCT05786417Phase 4Recruiting
- Sponsor
- Yale University
- Start
- May 2023
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of carvedilol in ischemic heart disease (IHD) (2 arms), sponsored by Yale University. Primary endpoint: Change in Quality of Life assessed using EQ-5D-5L at 45 days. Started May 2023; status: recruiting.
02
Drugs
carvedilol
03
Conditions
ischemic heart disease (IHD)
Beyond the preview
Go deeper on NCT05786417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786417.